BIO - הכנסה תפעולית לפני ניכוי פחת Bio-Rad

Bio-Rad Laboratories (BIO) profit dynamics depend on government science funding and demand for digital PCR. Current EBITDA figures visualize these processes, with the value stabilizing at 448.43. Revenue is generated through the supply of blood analysis systems to medical centers. The high reliability and maturity of the product portfolio make the company's solutions an essential foundation for global biomedical research.

This metric measures net cash flow from operating activities, deducting direct costs from revenue to determine the actual efficiency of the business. In the case of Bio-Rad Laboratories (BIO), high margins on absolute profit from core operations are driven by a closed equipment ecosystem and patent protection for reagents, making the price action on this chart a key indicator of earnings stability.